Oncology

Despite inquiry, FDA AdCom backs BMS Abecma approval

Despite the recent controversies surrounding chimeric antigen receptor (CAR)-T therapies, a US Food and Drug Administration (FDA) committee voted eight…

Norgine secures Pedmarqsi licence from Fennec in deal worth up to $272m

Fennec Pharmaceuticals has signed an exclusive licence agreement with Norgine to commercialise the former’s hearing loss therapy Pedmarqsi (sodium thiosulphate…

FDA approves BeiGene’s TEVIMBRA for oesophageal cancer

The US Food and Drug Administration (FDA) has approved BeiGene's TEVIMBRA (tislelizumab-jsgr) for the treatment of adults with unresectable or…

Lamassu Bio secures US NIH grant for sarcoma treatment

Lamassu Bio has received a $2.05m grant from the US National Institutes of Health (NIH) and National Cancer Institute (NCI)…

Pearl Bio and Merck partner for discovery of cancer therapies

Synthetic biology company Pearl Bio has signed a licence, partnership and option agreement with Merck for the discovery of biologic…

Terns scores FDA orphan designation for CML therapy

The US Food and Drug Administration (FDA) has granted an orphan drug designation to Terns Pharmaceuticals’s TERN-701 for the treatment…

Merck completes acquisition of Harpoon Therapeutics

Merck & Co. (MSD) has concluded the acquisition of Harpoon Therapeutics to broaden its oncology pipeline. In January 2024, MSD…

BeiGene secures accelerated FDA approval for follicular lymphoma treatment

The US Food and Drug Administration (FDA) has granted accelerated approval to BeiGene’s Brukinsa (zanubrutinib) for patients with advanced forms…

Johnson & Johnson acquires Ambrx Biopharma for $2bn

Johnson & Johnson (J&J) has concluded the acquisition of clinical-stage biopharmaceutical company Ambrx Biopharma in a $2bn transaction. The companies…

FDA approves BMS’ Opdivo for urothelial carcinoma

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) for the first-line…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close